Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)

Clinical trial NCT04922047 · UNKNOWN

Trial details

NCT number: NCT04922047
Sponsor: RenJi Hospital
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Urinary Bladder Neoplasms Urologic Neoplasms Urogenital Neoplasms Antineoplastic Agents Urinary Bladder Diseases Tislelizumab Antineoplastic Agents, Immunological

Start date: 2021-06-01
Primary completion: 2021-12-01
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.